Advertisement

Topics

Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

16:20 EST 11 Jan 2019 | OncLive

Peter Voorhees, MD, discusses the clinical potential of adding daratumumab to bortezomib, lenalidomide, and dexamethasone in patients with multiple myeloma.

Original Article: Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma

NEXT ARTICLE

More From BioPortfolio on "Daratumumab/VRd Regimen Has Practice-Changing Potential in Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement